Nevertheless, JMJD3 deficiency was reported to promote malignant progression of human pancreatic carcinoma by decreasing the expression of C/EBPα, a potential inhibitory partner of E2F145,46. Here, CEBPA is linked to exocrine pancreatic carcinoma.